SignatureFD’s Nektar Therapeutics NKTR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $4.32K | Sell |
60
-10
| -14% | -$569 | ﹤0.01% | 2830 |
|
|
2025
Q4 | $2.96K | Sell |
70
-190
| -73% | -$10.6K | ﹤0.01% | 2863 |
|
|
2025
Q3 | $14.8K | Hold |
260
| – | – | ﹤0.01% | 2245 |
|
|
2025
Q2 | $6.72K | Buy |
260
+187
| +256% | +$2.1K | ﹤0.01% | 2493 |
|
|
2025
Q1 | $748 | Buy |
73
+60
| +462% | +$784 | ﹤0.01% | 3109 |
|
|
2024
Q4 | $186 | Hold |
13
| – | – | ﹤0.01% | 3229 |
|
|
2024
Q3 | $260 | Hold |
13
| – | – | ﹤0.01% | 3154 |
|
|
2024
Q2 | $248 | Hold |
13
| – | – | ﹤0.01% | 3043 |
|
|
2024
Q1 | $187 | Hold |
13
| – | – | ﹤0.01% | 3100 |
|
|
2023
Q4 | $113 | Sell |
13
-200
| -94% | -$1.51K | ﹤0.01% | 3084 |
|
|
2023
Q3 | $1.91K | Hold |
213
| – | – | ﹤0.01% | 2780 |
|
|
2023
Q2 | $1.84K | Hold |
213
| – | – | ﹤0.01% | 2827 |
|
|
2023
Q1 | $2.25K | Hold |
213
| – | – | ﹤0.01% | 2767 |
|
|
2022
Q4 | $7.23K | Sell |
213
-105
| -33% | -$5.08K | ﹤0.01% | 2287 |
|
|
2022
Q3 | $15K | Sell |
318
-32
| -9% | -$1.9K | ﹤0.01% | 1887 |
|
|
2022
Q2 | $20K | Buy |
350
+26
| +8% | +$1.64K | ﹤0.01% | 1781 |
|
|
2022
Q1 | $26K | Buy |
324
+53
| +20% | +$7.84K | ﹤0.01% | 1715 |
|
|
2021
Q4 | $55K | Buy |
271
+47
| +21% | +$10.2K | ﹤0.01% | 1289 |
|
|
2021
Q3 | $60K | Buy |
224
+3
| +1% | +$721 | ﹤0.01% | 1213 |
|
|
2021
Q2 | $57K | Sell |
221
-3
| -1% | -$830 | ﹤0.01% | 1215 |
|
|
2021
Q1 | $67K | Buy |
224
+3
| +1% | +$934 | ﹤0.01% | 1041 |
|
|
2020
Q4 | $56K | Buy |
221
+8
| +4% | +$2.07K | ﹤0.01% | 1018 |
|
|
2020
Q3 | $53K | Sell |
213
-4
| -2% | -$1.26K | ﹤0.01% | 955 |
|
|
2020
Q2 | $75K | Hold |
217
| – | – | ﹤0.01% | 797 |
|
|
2020
Q1 | $58K | Buy |
217
+2
| +0.9% | +$619 | 0.01% | 839 |
|
|
2019
Q4 | $70K | Sell |
215
-11
| -5% | -$3.19K | 0.01% | 853 |
|
|
2019
Q3 | $62K | Buy |
226
+11
| +5% | +$4.03K | 0.01% | 843 |
|
|
2019
Q2 | $115K | Buy |
215
+15
| +8% | +$7.52K | 0.01% | 572 |
|
|
2019
Q1 | $101K | Sell |
200
-2
| -1% | -$1.19K | 0.01% | 624 |
|
|
2018
Q4 | $99K | Sell |
202
-202
| -50% | -$122K | 0.01% | 586 |
|
|
2018
Q3 | $370K | Buy |
404
+400
| +10,000% | +$341K | 0.04% | 258 |
|
|
2018
Q2 | $3K | Buy |
+4
| New | +$4.61K | ﹤0.01% | 1660 |
|
|
2018
Q1 | – | Hold |
0
| – | – | – | 1757 |
|
|
2014
Q3 | – | Sell |
-67
| Closed | -$13K | – | 848 |
|
|
2014
Q2 | $13K | Buy |
+67
| New | +$11.8K | ﹤0.01% | 418 |
|
Other funds holding NKTR
BI
TSC
VCM
PM
AC
SignatureFD's NKTR Position: Q1 2026 in Review
SignatureFD reduced its Nektar Therapeutics (NKTR) stake by 14% in Q1 2026, selling an estimated $569 and leaving 60 shares worth $4.32K. The position accounts for ﹤0.01% of the portfolio, ranked #2830.
SignatureFD first reported a position in NKTR in Q2 2014 and has held it in 33 quarters since. The position peaked at $370K in Q3 2018. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.
- SignatureFD held 60 shares of Nektar Therapeutics worth $4.32K as of Q1 2026.
- SignatureFD sold 10 Nektar Therapeutics shares in Q1 2026, an estimated $569.
- Nektar Therapeutics made up ﹤0.01% of SignatureFD's portfolio in Q1 2026, its #2830 holding.
- SignatureFD first reported a position in Nektar Therapeutics in Q2 2014 and has held it in 33 quarters since.
- SignatureFD's Nektar Therapeutics position peaked at $370K in Q3 2018.
- 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.
Based on SignatureFD's 13F filing for Q1 2026, filed 7 Apr 2026.